title: In-stent restenosis after revascularization of myocardium with drug-eluting stents is accompanied by elevated level of blood plasma eosinophil cationic protein.
abstract: The aim of this study was to assess the involvement of eosinophil cationic protein, a marker of eosinophil activation, in the development of in-stent restenosis after drug-eluting stent implantation. Follow-up angiography at 6 to 12 months was performed in 32 patients who were treated with percutaneous coronary intervention and implantation of sirolimus-eluting stents. Blood plasma levels of eosinophil cationic protein (ECP) and total immunoglobulin E (IgE) were measured by enzyme-linked immunosorbent assay and the level of C-reactive protein (hs-CRP) by high-sensitivity nephelometry. According to angiography data, in-stent restenosis occurred in 13 patients, while 19 patients did not develop it. There were no differences between the hs-CRP and IgE levels in patients with or without restenosis. In contrast, ECP level was higher in patients with restenosis compared with that in patients without restenosis [17.7 ng/mL (11.2-24.0) vs. 9.0 ng/mL (6.4-12.9), p = 0.017]. The incidence of in-stent restenoses was 63% in patients with ECP level higher than or equal to 11 ng/mL, and 19% in patients with an ECP level lower than 11 ng/mL (p = 0.019). These findings suggest that elevated eosinophil activation may play an important role in the pathogenesis of in-stent restenosis after implantation of drug-eluting stents.
authors.affiliation: Cardiology Research Center, 3rd Cherepkovskaya Street, 15A, Moscow, 121 552, Russia. gabbasov@cardio.ru
authors.forename: Zufar A
authors.initials: ZA
authors.lastname: Gabbasov
authors.forename: Sergei G
authors.initials: SG
authors.lastname: Kozlov
authors.forename: Asiya E
authors.initials: AE
authors.lastname: Imaeva
authors.forename: Olga S
authors.initials: OS
authors.lastname: Saburova
authors.forename: Kirill A
authors.initials: KA
authors.lastname: Zykov
authors.forename: Valery P
authors.initials: VP
authors.lastname: Masenko
authors.forename: Vladimir N
authors.initials: VN
authors.lastname: Smirnov
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology*; D054855:Drug-Eluting Stents; D047150:Eosinophil Cationic Protein / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000379:methods*; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; D007073:Immunoglobulin E; D002097:C-Reactive Protein; D047150:Eosinophil Cationic Protein; D020123:Sirolimus